Applications of SGLT2 inhibitors beyond glycaemic control.

Autor: O'Hara DV; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.; Royal North Shore Hospital, St Leonards, New South Wales, Australia., Lam CSP; National Heart Centre Singapore, Duke-NUS Medical School, Singapore, Singapore.; Baim Institute for Clinical Research, Boston, MA, USA., McMurray JJV; School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK., Yi TW; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.; The George Institute for Global Health, University of New South Wales, Newtown, New South Wales, Australia., Hocking S; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.; Boden Initiative, Charles Perkins Centre, University of Sydney, Camperdown, New South Wales, Australia.; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Dawson J; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.; Department of Nutrition and Dietetics, St George Hospital, Kogarah, New South Wales, Australia., Raichand S; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.; Centre for the Health Economy (MUCHE), Macquarie University, Macquarie Park, New South Wales, Australia., Januszewski AS; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.; Department of Medicine (St. Vincent's Hospital), The University of Melbourne, Fitzroy, Victoria, Australia.; Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia., Jardine MJ; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia. megj@sydney.edu.au.; Department of Renal Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia. megj@sydney.edu.au.
Jazyk: angličtina
Zdroj: Nature reviews. Nephrology [Nat Rev Nephrol] 2024 Aug; Vol. 20 (8), pp. 513-529. Date of Electronic Publication: 2024 Apr 26.
DOI: 10.1038/s41581-024-00836-y
Abstrakt: Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinical trials of these therapies have demonstrated striking beneficial effects for various care goals, transforming the chronic disease therapeutic landscape. Cardiovascular safety studies in people with T2DM demonstrated that SGLT2 inhibitors reduce cardiovascular death and hospitalization for heart failure. Subsequent trials in participants with heart failure with reduced or preserved left ventricular ejection fraction demonstrated that SGLT2 inhibitors have beneficial effects on heart failure outcomes. In dedicated kidney outcome studies, SGLT2 inhibitors reduced the incidence of kidney failure among participants with or without diabetes. Post hoc analyses have suggested a range of other benefits of these drugs in conditions as diverse as metabolic dysfunction-associated steatotic liver disease, kidney stone prevention and anaemia. SGLT2 inhibitors have a generally favourable adverse effect profile, although patient selection and medication counselling remain important. Concerted efforts are needed to better integrate these agents into routine care and support long-term medication adherence to close the gap between clinical trial outcomes and those achieved in the real world.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: